clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Dyspepsia D004415 5 associated lipids
Pyelonephritis D011704 5 associated lipids
Erythema Nodosum D004893 5 associated lipids
Hand Dermatoses D006229 5 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Rickettsia Infections D012282 5 associated lipids
Splenic Diseases D013158 5 associated lipids
Boutonneuse Fever D001907 5 associated lipids
Syphilis D013587 6 associated lipids
Tuberculosis, Multidrug-Resistant D018088 6 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Pneumonia, Mycoplasma D011019 6 associated lipids
Skin Ulcer D012883 6 associated lipids
Bronchiolitis D001988 6 associated lipids
Whooping Cough D014917 6 associated lipids
Nocardia Infections D009617 6 associated lipids
Bronchitis D001991 6 associated lipids
Meningitis, Bacterial D016920 6 associated lipids
Bronchiectasis D001987 7 associated lipids
Stomach Diseases D013272 7 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Chlamydia Infections D002690 7 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Skin Diseases, Infectious D012874 7 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Klebsiella Infections D007710 7 associated lipids
Metaplasia D008679 7 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Tooth Discoloration D014075 7 associated lipids
Infant, Premature, Diseases D007235 7 associated lipids
Bacteriuria D001437 7 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Fistula D005402 8 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Enterocolitis, Pseudomembranous D004761 8 associated lipids
Renal Insufficiency D051437 8 associated lipids
Lymphadenitis D008199 8 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Leprosy D007918 8 associated lipids
Bacteremia D016470 9 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Periodontal Pocket D010514 9 associated lipids
Obstetric Labor, Premature D007752 9 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Cross Infection D003428 9 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Urethritis D014526 9 associated lipids
Urination Disorders D014555 9 associated lipids
Sinusitis D012852 9 associated lipids
Lung Diseases, Obstructive D008173 10 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Abnormalities, Drug-Induced D000014 10 associated lipids
Dermatitis, Exfoliative D003873 10 associated lipids
Hemophilia A D006467 10 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Osteomyelitis D010019 10 associated lipids
Dyspnea D004417 10 associated lipids
Hearing Disorders D006311 10 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Pancreatitis D010195 10 associated lipids
Influenza, Human D007251 11 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Exanthema D005076 11 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Shock, Septic D012772 11 associated lipids
Otitis Media D010033 12 associated lipids
Skin Neoplasms D012878 12 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Endophthalmitis D009877 12 associated lipids
Wound Infection D014946 12 associated lipids
Urticaria D014581 13 associated lipids
Rosacea D012393 13 associated lipids
Bradycardia D001919 13 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Abscess D000038 13 associated lipids
Radiation Injuries D011832 14 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Encephalitis D004660 15 associated lipids
HIV Seropositivity D006679 15 associated lipids
Synovitis D013585 15 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Dermatomycoses D003881 17 associated lipids
Ischemia D007511 18 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
Bronchial Spasm D001986 18 associated lipids
Peptic Ulcer D010437 19 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Tuberculosis D014376 20 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Bacterial Infections D001424 21 associated lipids
Myocardial Infarction D009203 21 associated lipids
Helicobacter Infections D016481 21 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Chen XZ et al. Synthesis and antibacterial activity of novel ketolides with 11,12-sulfur contained aryl alkyl side chains. 2011 Eur J Med Chem pmid:21130543
Jinda S et al. Personalized treatment in the eradication therapy for Helicobacter pylori. 2011 Int. J. Mol. Med. pmid:21132257
Bediwy AS et al. Induced Sputum Substance P in Children with Difficult-to-Treat Bronchial Asthma and Gastroesophageal Reflux: Effect of Esomeprazole Therapy. 2011 Int J Pediatr pmid:22253635
Kostamo P et al. Recent trends in primary antimicrobial resistance of Helicobacter pylori in Finland. 2011 Int. J. Antimicrob. Agents pmid:21084175
Chacko Y and Holtmann GJ Helicobacter pylori eradication and weight gain: has it opened a Pandora's box? 2011 Aliment. Pharmacol. Ther. pmid:21679208
Yamade M et al. Resistance of Helicobacter pylori to quinolones and clarithromycin assessed by genetic testing in Japan. 2011 J. Gastroenterol. Hepatol. pmid:21679250
Yang YJ and Sheu BS Sequential therapy in childhood Helicobacter pylori eradication: emphasis on drug compliance. 2011 J. Pediatr. pmid:21679964
Umezawa M et al. Clarithromycin and telithromycin increases interleukin-10 expression in the rat endometriosis model. 2011 Cytokine pmid:21665488
Kikuta H et al. Predominant Dissemination of PVL-Negative CC89 MRSA with SCCmec Type II in Children with Impetigo in Japan. 2011 Int J Pediatr pmid:22187567
Nikolousis E and Velangi M Two cases of aspergillus endocarditis in non neutropenic children on chemotherapy for acute lymphoblastic leukaemia. 2011 Hematol Rep pmid:22184529
van der Elst KC et al. Validation parameters cannot be obtained without using pure substance. 2011 J Pharm Biomed Anal pmid:21632195
Ernst P et al. Risk of herpes zoster in patients prescribed inhaled corticosteroids: a cohort study. 2011 BMC Pulm Med pmid:22177425
Uriel A and Lewthwaite P Malaria therapy in HIV: drug interactions between nevirapine and quinine. 2011 Int J STD AIDS pmid:22174067
Fujita Y et al. [A case of lung cancer complicated with active non-tuberculous mycobacterium (NTM) infection successfully treated with anti-cancer agents and anti-NTM agents]. 2011 Nihon Kokyuki Gakkai Zasshi pmid:22171491
Ishiguro T et al. [A case of follicular bronchiolitis in which progressive bronchiectasis developed over 7 years]. 2011 Nihon Kokyuki Gakkai Zasshi pmid:22171486
Zamorano J and Edwards J Combining antihypertensive and antihyperlipidemic agents - optimizing cardiovascular risk factor management. 2011 Integr Blood Press Control pmid:22162939
Matsui E et al. The influence of glycyrrhiza and antibiotics on the purgative action of sennoside a from Daiokanzoto in mice. 2011 Biol. Pharm. Bull. pmid:21881230
Cirioni O et al. Effect of the combination of clarithromycin and amikacin on Pseudomonas aeruginosa biofilm in an animal model of ureteral stent infection. 2011 J. Antimicrob. Chemother. pmid:21406436
Iakovlev EA et al. [Present stage of chemotherapy and chemoprophylaxis of rickettsiosis and Q fever]. 2011 Antibiot. Khimioter. pmid:22856156
Hügle T Immunology of fibrotic lung disease: managing infections whilst preventing autoimmunity? 2011 J Inflamm Res pmid:22096366
Randhawa GK and Kullar JS Bioremediation of pharmaceuticals, pesticides, and petrochemicals with gomeya/cow dung. 2011 ISRN Pharmacol pmid:22084712
Agudo S et al. Rapid detection of clarithromycin resistant Helicobacter pylori strains in Spanish patients by polymerase chain reaction-restriction fragment length polymorphism. 2011 Rev Esp Quimioter pmid:21412667
Ohta H et al. A case of cutaneous infection caused by mycobacterium szulgai with progression to acute respiratory distress syndrome. 2011 Clin Med Insights Case Rep pmid:22084610
Agrawal A et al. Role of Helicobacter pylori infection in the pathogenesis of minimal hepatic encephalopathy and effect of its eradication. 2011 Indian J Gastroenterol pmid:21416318
El-Enany NM et al. Spectrofluorimetric determination of sertraline in dosage forms and human plasma through derivatization with 9-fluorenylmethyl chloroformate. 2011 Chem Cent J pmid:21978386
Singh A et al. Mycobacteria in keloid. 2011 Lung India pmid:22084557
Vaghani SS and Patel MM pH-sensitive hydrogels based on semi-interpenetrating network (semi-IPN) of chitosan and polyvinyl pyrrolidone for clarithromycin release. 2011 Drug Dev Ind Pharm pmid:21417603
Micallef J et al. Two cases of aspiration of calcium tablets. 2011 Lung India pmid:22084552
Sohail MA et al. Serum sickness-like reaction with clarithromycin. 2011 J Hosp Med pmid:21480496
Ohe M and Hashino S A case of follicular B-cell lymphoma treated using clarithromycin. 2011 Korean J Hematol pmid:22065978
Schubel K et al. [Pleuropneumonia due to Mycobacterium chelonae]. 2011 Rev Mal Respir pmid:21482339
Cantarella G et al. Outcomes of structural fat grafting for paralytic and non-paralytic dysphonia. 2011 Acta Otorhinolaryngol Ital pmid:22064781
Mitchell CB et al. Infection with Mycobacterium immunogenum following a tattoo. 2011 J. Am. Acad. Dermatol. pmid:21496684
Khalil F and Läer S Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development. 2011 J. Biomed. Biotechnol. pmid:21716673
Bamias G et al. Atypical mycobacterial infection presenting as persistent skin lesion in a patient with ulcerative colitis. 2011 Case Rep Med pmid:22007233
Feng Y et al. Outbreak of a cutaneous Mycobacterium marinum infection in Jiangsu Haian, China. 2011 Diagn. Microbiol. Infect. Dis. pmid:21996361
Gitti Z et al. Clinical significance and antibiotic susceptibilities of nontuberculous mycobacteria from patients in Crete, Greece. 2011 Future Microbiol pmid:21958147
Lehours P et al. Genome sequencing reveals a phage in Helicobacter pylori. 2011 MBio pmid:22086490
Abbas O et al. Cutaneous non-tuberculous Mycobacterial infections: a clinical and histopathological study of 17 cases from Lebanon. 2011 J Eur Acad Dermatol Venereol pmid:20456544
Ermis F et al. Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer. 2011 South. Med. J. pmid:21886067
Ozdemir R et al. Clarithromycin in preventing bronchopulmonary dysplasia in Ureaplasma urealyticum-positive preterm infants. 2011 Pediatrics pmid:22123897
Wang H et al. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010. 2011 Int. J. Antimicrob. Agents pmid:21880469
Chuah SK et al. A new look at anti-Helicobacter pylori therapy. 2011 World J. Gastroenterol. pmid:22046084
Francesco VD et al. Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal. 2011 World J Gastrointest Pathophysiol pmid:21860834
Sezikli M et al. Efficacy of vitamins supplementation to therapy on Helicobacter pylori eradication in patients with low antioxidant capacity. 2011 Clin Res Hepatol Gastroenterol pmid:21856267
Mencacci A et al. Legionella pneumophila serogroup 3 pneumonia in a patient with low-grade 4 non-Hodgkin lymphoma: a case report. 2011 J Med Case Rep pmid:21849075
Sarma S et al. Mycobacterium abscessus bacteremia in an immunocompetent patient following a coronary artery bypass graft. 2011 J Cardiovasc Dis Res pmid:21716760
Bekar O et al. Kefir improves the efficacy and tolerability of triple therapy in eradicating Helicobacter pylori. 2011 J Med Food pmid:21186984
Asano N et al. Signet Ring Cell Gastric Cancer Occurring after Radiation Therapy for Helicobacter pylori-Uninfected Mucosa-Associated Lymphoid Tissue Lymphoma. 2011 Case Rep Gastroenterol pmid:21712948
Liou JM et al. Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies. 2011 Antimicrob. Agents Chemother. pmid:21189342
Therese KL et al. First report on isolation of Mycobacterium monacense from sputum specimen in India. 2011 Lung India pmid:21712923
Zarogoulidis P et al. Long-term respiratory follow-up of H1N1 infection. 2011 Virol. J. pmid:21702977
Khan MK et al. Bioequivalence study of two oral formulations of clarithromycin in human male subjects. 2011 Pak J Pharm Sci pmid:21190917
Boyanova L et al. Benefits of Helicobacter pylori cagE genotyping in addition to cagA genotyping: a Bulgarian study. 2011 Antonie Van Leeuwenhoek pmid:21701821
Molina-Infante J and Gisbert JP Levofloxacin in first-line eradication regimens for Helicobacter pylori: better test antibiotic susceptibility before treating. 2011 Gut pmid:21193443
Bohnert JA et al. Efflux inhibition by selective serotonin reuptake inhibitors in Escherichia coli. 2011 J. Antimicrob. Chemother. pmid:21700628
Zullo A et al. Sequential therapy for Helicobacter pylori eradication: is levofloxacin better? 2011 Gut pmid:21193446
Miendje Deyi VY et al. Practical use of GenoType® HelicoDR, a molecular test for Helicobacter pylori detection and susceptibility testing. 2011 Diagn. Microbiol. Infect. Dis. pmid:21696906
Tagliabue C et al. Efficacy of increasing dosages of clarithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia. 2011 J. Antimicrob. Chemother. pmid:21791441
de Vrese M et al. Probiotic lactobacilli and bifidobacteria in a fermented milk product with added fruit preparation reduce antibiotic associated diarrhea and Helicobacter pylori activity. 2011 J. Dairy Res. pmid:21871144
Ponte P et al. Borderline CD30+ cutaneous lymphoproliferative disorder: report of a case with expression of cytotoxic markers and response to clarithromycin. 2011 J. Cutan. Pathol. pmid:19922478
Kim SY and Jung SW [Helicobacter pylori eradication therapy in Korea]. 2011 Korean J Gastroenterol pmid:21873820
Kim JY et al. [Primary antibiotic resistance of Helicobacter pylori strains and eradication rate according to gastroduodenal disease in Korea]. 2011 Korean J Gastroenterol pmid:21873821
Selgrad M et al. Guidelines for treatment of Helicobacter pylori in the East and West. 2011 Expert Rev Anti Infect Ther pmid:21819326
Hajiioannou JK et al. Clarithromycin induced reversible sensorineural hearing loss. 2011 B-ENT pmid:21838098
Rodrigues L et al. Ethidium bromide transport across Mycobacterium smegmatis cell-wall: correlation with antibiotic resistance. 2011 BMC Microbiol. pmid:21332993
Mazis GA et al. Recurrent fluctuant mass of the wrist and forearm associated with chronic tenosynovitis by Mycobacterium kansasii. 2011 Orthopedics pmid:21598885
Green JS et al. Persistent neutrophilic meningitis in an immunocompetent patient after basilar skull fracture: case report. 2011 BMC Infect. Dis. pmid:21595944
Betal D and Macneill FA Chronic breast abscess due to Mycobacterium fortuitum: a case report. 2011 J Med Case Rep pmid:21592364
Sunagawa S et al. Comparison of drug sensitivity and genotypes of clinically isolated strains of levofloxacin-resistant Streptococcus pneumoniae obtained from Okinawa Island, the Japanese main island and Hong Kong. 2011 J. Antibiot. pmid:21587266
Earl AM et al. High quality draft genome sequence of Segniliparus rugosus CDC 945(T)= (ATCC BAA-974(T)). 2011 Stand Genomic Sci pmid:22675588
Andrade RJ and Tulkens PM Hepatic safety of antibiotics used in primary care. 2011 J. Antimicrob. Chemother. pmid:21586591
Hori K et al. Efficacy of 2-week, second-line Helicobacter pylori eradication therapy using rabeprazole, amoxicillin, and metronidazole for the Japanese population. 2011 Helicobacter pmid:21585610
Ramón-García S et al. Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen. 2011 Antimicrob. Agents Chemother. pmid:21576426
Choi JG et al. In Vitro and In Vivo Antibacterial Activity of Punica granatum Peel Ethanol Extract against Salmonella. 2011 Evid Based Complement Alternat Med pmid:19687188
Terkeltaub RA et al. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. 2011 Arthritis Rheum. pmid:21480191
Leppert W Pain management in patients with cancer: focus on opioid analgesics. 2011 Curr Pain Headache Rep pmid:21479998
Gamie Z et al. Posterior reversible encephalopathy syndrome in a child with cyclical vomiting and hypertension: a case report. 2011 J Med Case Rep pmid:21470405
Lombo B and Díez JG Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes. 2011 Core Evid pmid:21468241
Salman H and Lazarus HM Plerixafor for autologous CD34 cell mobilization. 2011 Core Evid pmid:21468240
Kuçukbayrak A et al. Vesiculobullous eruption of the right arm after intravenous clarithromycin. 2011 Indian J Pharmacol pmid:21455431
Chatterjee S et al. Clinical effectiveness and safety of gemifloxacin versus cefpodoxime in acute exacerbation of chronic bronchitis: A randomized, controlled trial. 2011 Indian J Pharmacol pmid:21455420
Anacleto TP et al. Studies of distribution and recurrence of Helicobacter spp. gastric mucosa of dogs after triple therapy. 2011 Acta Cir Bras pmid:21445468
Rathi SK Acne vulgaris treatment : the current scenario. 2011 Indian J Dermatol pmid:21572783
Bruhn O et al. Antimicrobial peptides and proteins of the horse--insights into a well-armed organism. 2011 Vet. Res. pmid:21888650
Seddon J and Bhagani S Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal. 2011 HIV AIDS (Auckl) pmid:22096404
Schor AM and Hellerstein A Rhabdomyolysis following a short course of clarythromycin. 2011 J Pediatr Pharmacol Ther pmid:22479165
Yang J et al. Exposure to trimethoprim/sulfamethoxazole but not other FDA category C and D anti-infectives is associated with increased risks of preterm birth and low birth weight. 2011 Int. J. Infect. Dis. pmid:21345707
Soriano F et al. Cefditoren in upper and lower community-acquired respiratory tract infections. 2011 Drug Des Devel Ther pmid:21340042
Quan F et al. Investigation of pulmonary infection pathogens in neurological intensive care unit. 2011 Ther Clin Risk Manag pmid:21339939
Fialho AB et al. Low prevalence of H. pylori infection in HIV-positive patients in the northeast of Brazil. 2011 BMC Gastroenterol pmid:21333017
Kontarakis N et al. Antibiotic prescriptions in primary health care in a rural population in Crete, Greece. 2011 BMC Res Notes pmid:21320356
Chin BS et al. The characteristics of metallo-β-lactamase-producing gram-negative bacilli isolated from sputum and urine: a single center experience in Korea. 2011 Yonsei Med. J. pmid:21319358
Lee J et al. Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes. 2011 Korean J. Intern. Med. pmid:21716591
Chahil N et al. Novel approach to treatment of rectal mucosa-associated lymphoid tissue lymphoma. 2011 BMJ Case Rep pmid:22715275
Hasosah M et al. Mucosa-associated lymphoid tissue lymphoma of the lacrimal gland: sustained remission after eradication of helicobacter pylori infection. 2011 Case Rep Gastrointest Med pmid:22606434
Pomares X et al. Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations. 2011 Int J Chron Obstruct Pulmon Dis pmid:22003290
Kariyawasam HH and Scadding GK Chronic rhinosinusitis: therapeutic efficacy of anti-inflammatory and antibiotic approaches. 2011 Allergy Asthma Immunol Res pmid:21966602
Yakoob J et al. Risk factors associated with Helicobacter pylori infection treatment failure in a high prevalence area. 2011 Epidemiol. Infect. pmid:20525411
Murakami K et al. Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study. 2011 Scand. J. Gastroenterol. pmid:21073372